Literature DB >> 11108900

The role of prothrombotic mutations in patients with Buerger's disease.

F Avcu1, E Akar, U Demirkiliç, E Yilmaz, N Akar, A Yalçin.   

Abstract

Thromboangiitis obliterans (TAO), or Buerger's disease, is a segmental occlusive inflammatory disorder of the arteries and veins, and etiopathogenesis is still obscure. In the present study we investigated the prevalence of prothrombin 20210 G-->A, factor V 1691 G-->A (Factor V Leiden), and factor V 4070 A-->G (His 1299 Arg) mutations, found to be associated with increased risk for vascular thrombosis, in 36 patients with TAO. We performed a case-control study of these mutations. The odds ratio for prothrombin 20210 A allele compared with G allele was 7.98 (95% confidence intervals 2. 45-25.93). Only this prothrombotic genetic factor was associated with the risk of TAO (p=0.032). In conclusion, carrying the prothrombin 20210 G-->A may be an important prothrombotic risk factor of TAO. This genetic predisposition must be screened in these patients routinely, and clinical importance must be supported by further investigations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108900     DOI: 10.1016/s0049-3848(00)00310-8

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices.

Authors:  Edwaldo Edner Joviliano; Renata Dellalibera-Joviliano; Marcelo Dalio; Paulo Rb Evora; Carlos E Piccinato
Journal:  Int J Angiol       Date:  2009

Review 2.  Thromboangiitis obliterans.

Authors:  Gregory Piazza; Mark A Creager
Journal:  Circulation       Date:  2010-04-27       Impact factor: 29.690

3.  Relationship between functional promoter polymorphism in the XBP1 gene (-116C/G) and atherosclerosis, ischemic stroke and hyperhomocysteinemia.

Authors:  Erkan Yilmaz; Rüçhan Akar; Serap Tiraş Eker; Gülhis Deda; Yekbun Adiguzel; Nejat Akar
Journal:  Mol Biol Rep       Date:  2009-08-11       Impact factor: 2.316

4.  A Rare Case of Thromboangiitis Obliterans of Bilateral Upper Extremities in an Adult Male.

Authors:  Toluwalope F Ejiyooye; Abimbola O Ajibowo; Sudha Dirisanala; Bukola Olagbende; Uchenna E Ezenagu; Aadil Khan
Journal:  Cureus       Date:  2022-05-13

5.  Thromboangiitis Obliterans (Buerger's Disease).

Authors:  Nicholas R Sinclair; Donald R Laub
Journal:  Eplasty       Date:  2015-04-10

6.  Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study.

Authors:  Annie M Bérard; Aurélie Bedel; Rémi Le Trequesser; Geneviève Freyburger; Alan Nurden; Sylvie Colomer; Viviane Guérin; Marie-Christine Vergnes; François Becker; Gabriel Camelot; Luc Bressolette; Philippe Lacroix; Jean-Pierre Cambou; Alessandra Bura-Rivière; Joseph Emmerich; Michel Darmon; Anne-Marie Deletraz; Samir Mesli; Brigitte Colombies; Virginie Vanbrugghe; Claude Conri; Joël Constans
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

7.  Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans.

Authors:  Fuchen Song; Bo Ji; Ting Chen
Journal:  Exp Ther Med       Date:  2018-07-11       Impact factor: 2.447

8.  Homozygous Factor V Leiden Thrombophilia in a Patient With Histologically Confirmed Thromboangiitis Obliterans.

Authors:  Mussa Mensa; Tom Dobbs; Zita M Jessop; Iain S Whitaker
Journal:  Clin Med Insights Case Rep       Date:  2019-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.